REV-MED recently signed a Memorandum of Understanding (MOU) with Bizarria Ginza Clinic and Tokyo Blanche Clinic in Japan for joint research in regenerative medicine using autologous stem cells.
Under this agreement, the three organizations will collaborate on:
- Researching new indications for stem cell therapy
- Conducting clinical studies and publishing joint papers
- Developing innovative beauty business models based on anti-aging medicine for the Japanese market
The partnership also focuses on leveraging REV-MED’s autologous adipose stem cell extraction kits to expand applications of stem cell therapies and invest in the development of related medical devices.
Dr. Masayoshi Kobayashi of Bizarria Ginza Clinic and Dr. Hyun-Seop Byun of Tokyo Blanche Clinic have extensive experience using adult stem cells derived from blood and adipose tissue to treat patients’ skin conditions. Dr. Byun is renowned not only in Korea but also in the Japanese medical aesthetics market.
REV-MED CEO Bongkeun Shin stated, “With this agreement, we plan to invest in multi-center research and development to ensure autologous stem cells are widely utilized across various fields in Japan.”
Source: HealthTrends (http://www.k-health.com)
REV-MED recently signed a Memorandum of Understanding (MOU) with Bizarria Ginza Clinic and Tokyo Blanche Clinic in Japan for joint research in regenerative medicine using autologous stem cells.
Under this agreement, the three organizations will collaborate on:
The partnership also focuses on leveraging REV-MED’s autologous adipose stem cell extraction kits to expand applications of stem cell therapies and invest in the development of related medical devices.
Dr. Masayoshi Kobayashi of Bizarria Ginza Clinic and Dr. Hyun-Seop Byun of Tokyo Blanche Clinic have extensive experience using adult stem cells derived from blood and adipose tissue to treat patients’ skin conditions. Dr. Byun is renowned not only in Korea but also in the Japanese medical aesthetics market.
REV-MED CEO Bongkeun Shin stated, “With this agreement, we plan to invest in multi-center research and development to ensure autologous stem cells are widely utilized across various fields in Japan.”
Source: HealthTrends (http://www.k-health.com)